Along with 32 ICC WES study [9], those studies also revealed novel mutations, such as those arising in chromatin remodeling genes (e.g., BAP1 and ARID1A) and metabolic genes (i.e., IDH1 and IDH2). This evidence concerns the gene BAP1 and intrahepatic cholangiocarcinoma.